Building a global platform in the regenerative medicine field
First written in FY2017-Q1. 21 of 23 entries say "Restated". Latest entry: FY2026-H1.
0 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「Our Group has a broad human cell business platform centered on iPS cell technology and aims to secure stable revenue by rolling out highly competitive products and services globally.」
The company has reaffirmed its policy of rolling out products and services globally on the basis of a human cell business platform centered on iPS cells. - FY2025-H1RestatedAnnual report
「We have a broad human cell business platform centered on iPS cells and are rolling out highly competitive products and services worldwide as short- to medium-term revenue pillars.」
The company has reaffirmed its policy of rolling out products and services worldwide on the basis of a human cell business platform centered on iPS cells and making it a short- to medium-term revenue pillar. - FY2024-Q3RestatedAnnual report
「We have a broad human cell business platform centered on iPS cells and are rolling out highly competitive products and services worldwide as short- to medium-term revenue pillars.」
The company has reaffirmed its policy of rolling out products and services worldwide on the basis of a human cell business platform centered on iPS cells and making it a short- to medium-term revenue pillar. - FY2024-Q2RestatedAnnual report
「We have a broad human cell business platform centered on iPS cells and are rolling out highly competitive products and services worldwide as short- to medium-term revenue pillars.」
The company has reaffirmed its policy of rolling out products and services worldwide on the basis of a human cell business platform centered on iPS cells. - FY2024-Q1RestatedAnnual report
「We have a broad human cell business platform centered on iPS cells and are rolling out highly competitive products and services worldwide as short- to medium-term revenue pillars.」
The company has reaffirmed its policy of rolling out products and services worldwide on the basis of a human cell business platform centered on iPS cells and making it a short- to medium-term revenue pillar. - FY2023-Q3RestatedAnnual report
「We have a broad human cell business platform centered on iPS cells and are rolling out highly competitive products and services worldwide as short- to medium-term revenue pillars.」
The company has reaffirmed its policy of rolling out products and services worldwide on the basis of a human cell business platform centered on iPS cells and making it a short- to medium-term revenue pillar. - FY2023-Q2RestatedAnnual report
「We have a broad human cell business platform centered on iPS cells and are rolling out highly competitive products and services worldwide as short- to medium-term revenue pillars.」
The company has reaffirmed its policy of rolling out products and services worldwide on the basis of a human cell business platform centered on iPS cells and making it a short- to medium-term revenue pillar. - FY2023-Q1RestatedAnnual report
「We have a broad human cell business platform centered on iPS cells and are rolling out highly competitive products and services worldwide as short- to medium-term revenue pillars.」
The company has reaffirmed its policy of expanding globally and generating revenue in the short to medium term on the basis of a human cell business platform centered on iPS cells. - FY2022-Q3RestatedAnnual report
「We have a broad human cell business platform centered on iPS cells and are rolling out highly competitive products and services worldwide as short- to medium-term revenue pillars.」
The company has reaffirmed its policy of rolling out products and services worldwide on the basis of a human cell business platform centered on iPS cells and making it a short- to medium-term revenue pillar. - FY2022-Q1RestatedAnnual report
「We have a broad human cell business platform centered on iPS cells and are rolling out highly competitive products and services worldwide as short- to medium-term revenue pillars.」
The company has reaffirmed its policy of rolling out products and services worldwide on the basis of a human cell business platform centered on iPS cells. - FY2021RestatedAnnual report
「We aim to become a market leader in this field by developing the Research Support Business, which provides iPS cell-related research reagents and drug discovery support services as a short- to medium-term business pillar, and by actively investing in the Medical Business, which is expected to address a huge market as a medium- to long-term growth strategy.」
The company has reaffirmed its policy of making the Research Support Business a short- to medium-term pillar and the Medical Business a medium- to long-term growth business, with the aim of becoming a market leader in the iPS cell and regenerative medicine fields. - FY2021-Q3RestatedAnnual report
「We have a broad human cell business platform centered on iPS cells and are rolling out highly competitive products and services worldwide as short- to medium-term revenue pillars.」
The company has reaffirmed its policy of rolling out products and services worldwide on the basis of a human cell business platform centered on iPS cells. - FY2021-Q2RestatedAnnual report
「We have a broad human cell business platform centered on iPS cells and are rolling out highly competitive products and services worldwide as short- to medium-term revenue pillars.」
The company has reaffirmed its policy of rolling out products and services worldwide on the basis of a human cell business platform centered on iPS cells. - FY2021-Q1RestatedAnnual report
「We have a broad human cell business platform centered on iPS cells and are rolling out highly competitive products and services worldwide as short- to medium-term revenue pillars.」
The company has reaffirmed its policy of rolling out products and services worldwide on the basis of a human cell business platform centered on iPS cells. - FY2020RestatedAnnual report
「We aim to become a market leader in this field by developing the Research Support Business, which provides iPS cell-related research reagents and drug discovery support services as a short- to medium-term business pillar, and by actively investing in the Medical Business, which is expected to address a huge market as a medium- to long-term growth strategy.」
The company has reaffirmed its policy of aiming to become a market leader in the iPS cell and regenerative medicine fields through the Research Support Business and the Medical Business. - FY2019-Q3RestatedAnnual report
「Our Group has a world-leading technology platform relating to human iPS cells and is advancing this business by leveraging its strengths.」
The company has reaffirmed its policy of leveraging its world-leading technology platform for human iPS cells to advance its business. - FY2019-Q2RestatedAnnual report
「Our Group has a world-leading technology platform relating to human iPS cells and is advancing this business by leveraging its strengths.」
The company has reaffirmed its policy of leveraging its world-leading technology platform for human iPS cells to advance its business. - FY2018RestatedAnnual report
「Our Group places iPS cells at the core of its business and operates in two business areas: the Research Support Business and the Medical Business.」
The company has reaffirmed its policy of placing iPS cells at the core of its business and building a business foundation in the regenerative medicine field through both research support and medical operations. - FY2018-Q3RestatedAnnual report
「Our Group has a world-leading technology platform relating to human iPS cells and is advancing this business segment by leveraging its strengths.」
In connection with a global platform in the regenerative medicine field, the company states that it has a world-leading technology platform for human iPS cells and will use it to advance its business. - FY2017RestatedAnnual report
「Our Group will continue developing the business platform needed to expand its regenerative medicine business.」
The company has reaffirmed its policy of continuing to develop and industrialize its regenerative medicine business platform. - FY2017-Q3AdvancedAnnual report
「Against this economic backdrop, our Group has begun a full-scale entry into the regenerative medicine field while selling iPS cell-related reagents and providing cell products and services that support drug discovery.」
The company explicitly stated that it had begun a full-scale entry into the regenerative medicine field, moving from its previous entry policy to the stage of launching specific businesses. - FY2017-Q2RestatedAnnual report
「Going forward, we will further accelerate our efforts to enter the regenerative medicine field and promptly build a global platform in this field.」
The company has reiterated its policy of accelerating entry into the regenerative medicine field and promptly building a global platform. - FY2017-Q1First statedAnnual report
「Going forward, we will further accelerate our efforts to enter the regenerative medicine field and promptly build a global platform in this field.」
This is the first confirmation of the goal of promptly establishing a global business foundation in the regenerative medicine field.